{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:50:04Z","timestamp":1767833404441,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting therapy efficacy. Although cutaneous side effects are common, only very few cases of cutaneous lupus erythematosus have been reported under anti-PD-1 immunotherapy. So far, no case of cutaneous lupus has been described under treatment with cemiplimab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>For the first time, we report the case of a patient with advanced squamous cell carcinoma, who developed clinical and histological findings in sun-exposed skin that were consistent with anti-SS-A\/Ro antibody-positive subacute cutaneous lupus erythematosus (SCLE) under treatment with cemiplimab. Additionally, laboratory chemical analyses revealed a severe immune-related hepatitis without clinical symptoms. Both, the SCLE and the hepatitis, resolved after the administration of topical and systemic steroids and the discontinuation of anti-PD-1 therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with cemiplimab can be associated with the appearance of cutaneous lupus erythematosus in sun-exposed areas. Application of topical and systemic glucocorticoids can lead to a rapid resolution of the skin eruptions. Moreover, our case illustrates the possibility of simultaneously occurring severe immune-related adverse events. This highlights the importance of additional diagnostics to avoid overlooking additional immune-related adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1324231","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:53:52Z","timestamp":1702032832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab \u2013 a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Simon","family":"Fietz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"de Vos-Hillebrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Sirokay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00320-5","article-title":"Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus","volume":"20","author":"Bolton","year":"2020","journal-title":"Drugs R D"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106176","article-title":"Drug-induced lupus: an update on its dermatologic aspects","volume":"18","author":"Marzano","year":"2009","journal-title":"Lupus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2013.10393","article-title":"Cutaneous lupus erythematosus","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15184","article-title":"Cemiplimab in advanced cutaneous squamous cell carcinoma","volume":"34","author":"Naik","year":"2021","journal-title":"Dermatol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10110.x","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.017","article-title":"Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy","volume":"145","author":"Andersson","year":"2021","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15316","article-title":"Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab","volume":"47","author":"Ogawa-Momohara","year":"2020","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"B14","unstructured":""},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000587","article-title":"Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases","volume":"29","author":"Blakeway","year":"2019","journal-title":"Melanoma Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13538","article-title":"Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review","volume":"62","author":"Diago","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000536","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review","volume":"29","author":"Zitouni","year":"2019","journal-title":"Melanoma Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000523800","article-title":"Nivolumab-Induced de novo Discoid Lupus Erythematosus","volume":"14","author":"Manjunath","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12681","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab","volume":"59","author":"Liu","year":"2018","journal-title":"Australas J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13030\/qt4md713j8","DOI":"10.5070\/D32510045821","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13432","article-title":"Bullous lupus under nivolumab treatment for lung cancer: A case report with systematic literature review","volume":"39","author":"Wouters","year":"2019","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/0961203317691369","article-title":"Trigger factors of cutaneous lupus erythematosus: a review of current literature","volume":"26","author":"Szcz\u0119ch","year":"2017","journal-title":"Lupus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15099","article-title":"Radiation-induced subacute cutaneous lupus erythematosus","volume":"47","author":"De Caux","year":"2022","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1324231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:53:54Z","timestamp":1702032834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1324231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2023.1324231"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1324231","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"article-number":"1324231"}}